XORTX Historical Income Statement

XRTX Stock

USD 1.21 0.03 2.54%

Historical analysis of XORTX Therapeutics income statement accounts such as Selling General Administrative of 1 M, Other Operating Expenses of 2.4 M, Total Operating Expenses of 2.4 M or Depreciation And Amortization of 103.2 K can show how well XORTX Therapeutics performed in making a profits. Evaluating XORTX Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of XORTX Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining XORTX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether XORTX Therapeutics is a good buy for the upcoming year.

XORTX Therapeutics Net Income

(3 Million)

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

About XORTX Income Statement Analysis

XORTX Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to XORTX Therapeutics shareholders. The income statement also shows XORTX investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

XORTX Therapeutics Income Statement Chart

At this time, XORTX Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 3.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 1 M in 2024.

Selling General Administrative Other Operating Expenses Total Operating Expenses Research Development

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of XORTX Therapeutics. It is also known as XORTX Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from XORTX Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.At this time, XORTX Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 3.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 1 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	17.9K	55.5K	139.7K	146.7K
Research Development	669.1K	6.5M	3.2M	1.7M

Reconciled Depreciation Research Development

XORTX Therapeutics income statement Correlations

	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Net Income	Depreciation And Amortization	Interest Expense	Total Other Income Expense Net	Income Tax Expense	Net Interest Income	Net Income From Continuing Ops	Research Development	Reconciled Depreciation	Interest Income	Selling And Marketing Expenses
Selling General Administrative		0.9	-0.9	-0.9	-0.91	0.9	-0.85	-0.85	0.53	-0.33	0.72	-0.32	-0.54	-0.82	0.82	0.48	0.34	-0.27
Other Operating Expenses	0.9		-0.93	-0.93	-0.94	1.0	-0.91	-0.91	0.5	-0.41	0.8	-0.4	-0.48	-0.91	0.96	0.41	0.21	-0.17
Operating Income	-0.9	-0.93		1.0	1.0	-0.93	0.88	0.88	-0.75	0.53	-0.91	0.51	0.36	0.83	-0.94	-0.69	-0.52	0.49
Ebit	-0.9	-0.93	1.0		1.0	-0.93	0.88	0.88	-0.75	0.53	-0.91	0.51	0.36	0.83	-0.94	-0.69	-0.52	0.49
Ebitda	-0.91	-0.94	1.0	1.0		-0.94	0.88	0.88	-0.75	0.53	-0.91	0.51	0.36	0.84	-0.94	-0.69	-0.51	0.49
Total Operating Expenses	0.9	1.0	-0.93	-0.93	-0.94		-0.91	-0.91	0.5	-0.41	0.8	-0.4	-0.48	-0.91	0.96	0.41	0.21	-0.17
Income Before Tax	-0.85	-0.91	0.88	0.88	0.88	-0.91		1.0	-0.57	0.27	-0.63	0.25	0.26	0.98	-0.89	-0.49	-0.3	0.3
Net Income	-0.85	-0.91	0.88	0.88	0.88	-0.91	1.0		-0.57	0.27	-0.63	0.25	0.26	0.98	-0.89	-0.49	-0.3	0.3
Depreciation And Amortization	0.53	0.5	-0.75	-0.75	-0.75	0.5	-0.57	-0.57		-0.49	0.78	-0.47	0.22	-0.44	0.64	0.99	0.91	-0.9
Interest Expense	-0.33	-0.41	0.53	0.53	0.53	-0.41	0.27	0.27	-0.49		-0.64	0.99	0.18	0.26	-0.48	-0.48	-0.42	0.41
Total Other Income Expense Net	0.72	0.8	-0.91	-0.91	-0.91	0.8	-0.63	-0.63	0.78	-0.64		-0.63	-0.25	-0.58	0.86	0.73	0.57	-0.56
Income Tax Expense	-0.32	-0.4	0.51	0.51	0.51	-0.4	0.25	0.25	-0.47	0.99	-0.63		0.17	0.24	-0.47	-0.47	-0.41	0.4
Net Interest Income	-0.54	-0.48	0.36	0.36	0.36	-0.48	0.26	0.26	0.22	0.18	-0.25	0.17		0.36	-0.28	0.25	0.33	-0.32
Net Income From Continuing Ops	-0.82	-0.91	0.83	0.83	0.84	-0.91	0.98	0.98	-0.44	0.26	-0.58	0.24	0.36		-0.87	-0.35	-0.15	0.15
Research Development	0.82	0.96	-0.94	-0.94	-0.94	0.96	-0.89	-0.89	0.64	-0.48	0.86	-0.47	-0.28	-0.87		0.55	0.39	-0.29
Reconciled Depreciation	0.48	0.41	-0.69	-0.69	-0.69	0.41	-0.49	-0.49	0.99	-0.48	0.73	-0.47	0.25	-0.35	0.55		0.94	-0.93
Interest Income	0.34	0.21	-0.52	-0.52	-0.51	0.21	-0.3	-0.3	0.91	-0.42	0.57	-0.41	0.33	-0.15	0.39	0.94		-0.83
Selling And Marketing Expenses	-0.27	-0.17	0.49	0.49	0.49	-0.17	0.3	0.3	-0.9	0.41	-0.56	0.4	-0.32	0.15	-0.29	-0.93	-0.83

Click cells to compare fundamentals

XORTX Therapeutics Account Relationship Matchups

XORTX Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Selling General Administrative	506.2K	1.1M	1.6M	2.3M	1.4M	1.0M
Other Operating Expenses	566.0K	1.3M	2.9M	9.9M	3.2M	2.4M
Operating Income	(566.0K)	(1.3M)	(4.1M)	(10.7M)	(6.6M)	(6.2M)
Ebit	(566.0K)	(1.3M)	(4.1M)	(10.7M)	(6.6M)	(6.2M)
Ebitda	(546.1K)	(1.3M)	(4.1M)	(10.6M)	(6.5M)	(6.1M)
Total Operating Expenses	566.0K	1.3M	2.9M	9.9M	3.2M	2.4M
Income Before Tax	(629.6K)	(1.3M)	(1.3M)	(7.0M)	(2.9M)	(3.0M)
Net Income	(629.6K)	(1.3M)	(1.3M)	(7.0M)	(2.9M)	(3.0M)
Depreciation And Amortization	19.9K	16.0K	14.0K	55.5K	98.3K	103.2K
Interest Expense	15.5K	22.3K	37.2K	13.5K	4.4K	0.0
Total Other Income Expense Net	(26.4K)	(181.9K)	1.6M	5.5M	3.7M	3.9M
Income Tax Expense	37.2K	13.5K	4.4K	0.0	(0.01)	(0.0095)
Net Interest Income	(37.2K)	(13.5K)	(1.6M)	(825.4K)	253.5K	266.2K
Net Income From Continuing Ops	(629.6K)	(1.3M)	(1.7M)	(7.0M)	(2.2M)	(2.3M)
Research Development	39.9K	277.5K	669.1K	6.5M	3.2M	1.7M
Reconciled Depreciation	19.9K	20.4K	17.9K	55.5K	139.7K	146.7K
Net Income Applicable To Common Shares	(629.6K)	(1.3M)	(1.7M)	(9.5M)	(8.5M)	(8.1M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

XORTX Historical Income Statement

XORTX Therapeutics Net Income

(3 Million)

About XORTX Income Statement Analysis

XORTX Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

XORTX Therapeutics income statement Correlations

XORTX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

XORTX Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for XORTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Reconciled Depreciation	+ 0.99	Depreciation And Amortization

Research Development	- 0.94	Ebitda
Total Operating Expenses	- 0.94	Ebitda
Research Development	- 0.94	Ebit
Research Development	- 0.94	Operating Income
Ebitda	- 0.94	Other Operating Expenses
Selling And Marketing Expenses	- 0.93	Reconciled Depreciation